Insights
Search Results
Client Highlights
7.27.26
Wilson Sonsini Advises Oak Hill Bio on IP Matters in Proposed Business Combination with RACC
On July 27, 2026, OHB Pediatrics Ltd. (dba Oak Hill Bio), a clinical-stage rare disease therapeutics company, and Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announced that they had entered into a definitive business combination agreement. In connection with consummation of the transaction, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol OAKH. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on IP matters related to the transaction.
Client Highlights
6.10.26
Wilson Sonsini Advises SonoThera on Patent Matters Related to Oversubscribed $125 Million Series B
On June 10, 2026, SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. Wilson Sonsini Goodrich & Rosati advised SonoThera on patent matters related to the transaction.
Client Highlights
6.01.26
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to $32.5 Million Series A Financing
On June 1, 2026, Oak Hill Bio, a clinical-stage rare disease therapeutics company, announced the closing of a $32.5 million Series A financing. The round was co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
Client Highlights
5.04.26
Firm Advises Candid Therapeutics on Patent Matters Related to Its $2 Billion Acquisition by UCB
On May 3, 2026, UCB, a global biopharmaceutical company, announced a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers. Under the terms of the agreement, UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises Frazier Life Sciences on IP Matters Related to Immutrin’s $87 Million Series A
On March 24, 2026, Immutrin, a biotechnology company developing next generation antibody therapy to reverse amyloidosis, announced it has successfully raised $87 million in a Series A financing. The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. Wilson Sonsini Goodrich & Rosati advised Frazier Life Sciences on patent matters related to the transaction.
Client Highlights
3.02.26
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio
On March 2, 2026, Rallybio and Candid Therapeutics, a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (TCE) therapeutics for autoimmune diseases, announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction. The combined company expects to operate under the name Candid Therapeutics and trade on Nasdaq under the ticker symbol CDRX. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Client Highlights
1.22.26
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to License Agreement with Bristol Myers Squibb
On January 22, 2026, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), and Tumor Activated Immunomodulator (TRACIr) platforms, announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop a tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Wilson Sonsini Goodrich & Rosati advised Janux on patent matters related to the transaction.
Client Highlights
1.09.26
Wilson Sonsini Advises Link Cell Therapies on Strategic Collaboration with Johnson & Johnson
On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.
Client Highlights
12.16.25
Wilson Sonsini Advises Link Cell Therapies on Series A Financing
On December 15, 2025, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the transaction.
Client Highlights
10.01.25
Firm Advises Predicta Biosciences on IP Matters Related to Oversubscribed $23.4 Million Series A
On October 1, 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, announced it has raised an oversubscribed $23.4 million Series A financing led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute, and Myeloma Solutions Fund. Wilson Sonsini Goodrich & Rosati advised Predicta on IP matters related to the transaction.
Client Highlights
4.15.25
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to Exclusive License Agreement with Roche
On April 15, 2025, Oak Hill Bio, a biotechnology company focused on acquiring and developing life-changing rare disease therapeutics, entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). Rugonersen is an ASO designed as a potential best-in-class treatment for individuals with Angelman syndrome, a rare, genetic neurodevelopmental condition for which there is no approved disease-modifying treatment. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
Client Highlights
1.07.25
Firm Advises Candid Therapeutics on Agreement with WuXi Biologics
On January 6, 2025, Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell engager developed by WuXi Biologics’ proprietary universal multispecific antibody platform, WuXiBody™. Candid plans to complete IND enabling studies to enable first-in-human studies in the first half of 2026. Wilson Sonsini Goodrich & Rosati advised Candid on technology transactions and patent matters related to the transaction.
Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment and development and sales milestones totaling up to $925 million, as well as royalties.
The Wilson Sonsini team advising Candid on the transaction includes:
Technology Transactions
Norm Hovijitra
Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment and development and sales milestones totaling up to $925 million, as well as royalties.
The Wilson Sonsini team advising Candid on the transaction includes:
Technology Transactions
Norm Hovijitra